Virtual panel discussion features experts from UPMC, SparingVision, Avista Therapeutics
|
Click the button above to visit the virtual discussion on Crowdcast. Once on the Crowdcast platform, click the green “Watch Replay” button and confirm via your email.
The discussion, which included audience Q&A, was held Thursday, March 21, 2024, at 2:00 p.m. ET.
In this expert panel discussion — co-hosted by the Center for Connected Medicine (CCM) and the Institute for Precision Medicine at UPMC and University of Pittsburgh — industry leaders in the field of gene therapy discuss the future of these innovative therapies, major milestones achieved, and significant advances on the horizon.
Expert panelists
Moderated by Alexander Anetakis, MD, a vitreo-retinal surgeon at UPMC, and Physician-Advisor, UPMC Enterprises, the panel includes the following experts:
- Dan Chung, MD, Chief Medical Officer, SparingVision
- Rob Lin, PhD, Chief Executive Officer, Avista Therapeutics
Topics for discussion
The following topics will be addressed in the discussion:
- Long-term efficacy of gene therapies and degeneration over time.
- Addressing the high costs and accessibility of gene therapies, including the challenging manufacturing process.
- Optimizing the application and delivery methods of gene therapies, including with combined other treatments.
- Expanding targets for gene therapies beyond specific mutations.
|
Click the button above to visit the virtual discussion on Crowdcast. Once on the Crowdcast platform, click the green “Watch Replay” button and confirm via your email.
Related resources from the CCM
Visit the Institute for Precision Medicine at University of Pittsburgh and UPMC.
Research report: AI offers potential solution to challenge of identifying clinical trial participants
Summit recap report: Top of Mind for Life Sciences Summit 2023 recap and highlights
